Positive results in AML with belinostat and idarubicin
-Data were presented at American Society of Hematology (ASH) meeting in San
Francisco Dec 6-9, 2008-
Copenhagen, Denmark - December 8, 2008- TopoTarget A/S (OMX: TOPO) announces
that belinostat monotherapy and belinostat in combination with idarubicin
shows promising effect in acute leukemia in an ongoing Phase I/II
international study.
“These are remarkable results obtained in a very difficult to treat population
of elderly patients who usually do not tolerate intensive chemotherapy.” Said
professor Peter Buhl Jensen, MD and CEO of TopoTarget. “In our labs we have
seen surprisingly good effect of prolonged belinostat administration and one
of the promising results of this study is a complete response obtained in a
patient treated with belinostat monotherapy as a 48 hours continuous infusion
(CIV). It is a completely new way of administering this drug type. We have
patented the invention and it is very promising that we already in phase I can
see a clear anticancer effect. Peter Buhl Jensen continues: “Belinostat is the
only compound in its class that can be given as a capsule, intravenous (IV) and
now also as continuous infusion (CIV).This additional new way of administering
belinostat could be clinically and commercially advantageous in certain
cancers.”
TopoTarget A/S
For further information, please contact:
Ulla Hald Buhl Telephone +45 39 17 83 92
Director IR & Communications Mobile +45 21 70 10 49
